Overview
Autosomal recessive intermediate Charcot-Marie-Tooth disease (AR-ICMT) is a group of rare inherited peripheral neuropathies that share features of both demyelinating (CMT type 1) and axonal (CMT type 2) forms of Charcot-Marie-Tooth disease. The term 'intermediate' refers to nerve conduction velocities (NCVs) that fall between the typical ranges for demyelinating and axonal CMT, generally between 25 and 45 m/s in the median motor nerve. This condition primarily affects the peripheral nervous system, leading to progressive weakness and atrophy of the distal muscles of the limbs, particularly the feet and hands, along with sensory impairment. Several genetic subtypes have been identified within this group, including CMTRIA (caused by mutations in the GDAP1 gene), CMTRIB (KARS1 gene), CMTRIC (PLEKHG5 gene), and CMTRID (COX6A1 gene), among others. Clinical features typically include progressive distal muscle weakness and wasting, foot deformities such as pes cavus (high-arched feet) and hammer toes, difficulty walking, reduced or absent deep tendon reflexes, and variable sensory loss affecting vibration and pain perception. Some subtypes may also present with additional features such as hearing loss, vocal cord paresis, or diaphragmatic weakness depending on the specific genetic cause. Onset is generally in childhood or adolescence, though this can vary by subtype. Disease severity ranges from mild to severe, with some patients requiring mobility aids. There is currently no cure for AR-ICMT. Treatment is supportive and symptomatic, including physical therapy and occupational therapy to maintain muscle strength and function, orthotic devices (such as ankle-foot orthoses) to improve gait, and surgical intervention for severe skeletal deformities when necessary. Pain management and regular monitoring by a multidisciplinary team including neurologists, physiatrists, and orthopedic specialists are recommended.
Also known as:
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Variable
Can begin at different ages, from infancy through adulthood
Treatments
No FDA-approved treatments are currently listed for Autosomal recessive intermediate Charcot-Marie-Tooth disease.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Autosomal recessive intermediate Charcot-Marie-Tooth disease at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Autosomal recessive intermediate Charcot-Marie-Tooth disease.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Autosomal recessive intermediate Charcot-Marie-Tooth disease.
Community
No community posts yet. Be the first to share your experience with Autosomal recessive intermediate Charcot-Marie-Tooth disease.
Start the conversation →Latest news about Autosomal recessive intermediate Charcot-Marie-Tooth disease
No recent news articles for Autosomal recessive intermediate Charcot-Marie-Tooth disease.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Autosomal recessive intermediate Charcot-Marie-Tooth disease
What is Autosomal recessive intermediate Charcot-Marie-Tooth disease?
Autosomal recessive intermediate Charcot-Marie-Tooth disease (AR-ICMT) is a group of rare inherited peripheral neuropathies that share features of both demyelinating (CMT type 1) and axonal (CMT type 2) forms of Charcot-Marie-Tooth disease. The term 'intermediate' refers to nerve conduction velocities (NCVs) that fall between the typical ranges for demyelinating and axonal CMT, generally between 25 and 45 m/s in the median motor nerve. This condition primarily affects the peripheral nervous system, leading to progressive weakness and atrophy of the distal muscles of the limbs, particularly the
How is Autosomal recessive intermediate Charcot-Marie-Tooth disease inherited?
Autosomal recessive intermediate Charcot-Marie-Tooth disease follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.